Tay-Sachs disease (TSD), an autosomal recessive neurodegenerative condition, is the result of a deficiency of p-hexosaminidase A (hex A). Heterozygotic individuals are screened by analysis for hex A and hex B activities; the percent of hex A is the criticaldeterminant of carrier vs noncarrier status. Most laboratories use a heat-inactivation assay that exploitsthe differentialthermolabilityof the isoenzymes. However, we have found a reciprocal relation between the apparent Ieukocyte hex A activity and the amount of the sample used in the assay; i.e., a significant increase in the percent of hex A activity with decreasing amounts of sample. Three sets of data indicate that this phenomenon was caused by an effect on the hex B isoenzyme and not on hex A. This variation in hex A activity with sample amount was not observed when a hex A-specific substrate was used. This phenomenon was also not seen in assays of leukocytes from carriers for Sandhoff disease, a conditionassociated with a reduction in the amount of hex B. Finally, when leukocytes from a TSD homozygote, containing almost no hex A, were analyzed, marked increases in the percent of hex A were observed with decreasing sample concentrations. These data indicate that misdiagnoses could result from variations in sample concentrations used for TSD carrier testing and support the view that the leukocyte concentrations used for these assays should be standardized. 
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Materials and Methods

Materials
Samples
We obtained leukocyte samples from apparently healthy normal control subjects and from patients referred to our Tay-Sachs Disease Prevention Program. Included in the analysis were three obligate heterozygotes for Sandhoff disease, i.e., persons who had a child with Sandhoff disease. The remaining samples were from individuals who were diagnosed as carriers of TSD or Sandhoff disease on the basis of our laboratory studies. One individual who was homozygous for TSD was also included in the study.
These experiments were done in accord with the ethical standards of the E. K. Shriver Center. 
Results
Effects of Sample Concentration on the Heat-Inactivation
Analysis of Hex A and Hex B
To determine the effect of varying the concentration of the sonicate on the apparent percent of leukocyte hex A 
0.01), as determined by the Student's t-test.
The effect of a 10-fold variation in sample concentration (2 and 20 jig of protein) was analyzed in two normal controls and one TSD patient (Table 1) . Persons with TSD have little or no hex A because of mutations in the a-subunit gene of hexosaminidase.
As seen in Table 1 Direct Analysisof Hex A The heat-inactivation assay described above indirectly yields the percent of hex A activity, because it is assumed that the heat treatment inactivates only hex A, and the remaining activity is due to hex B. To study directly the effects of varying sample concentration on hex A activity in the leukocyte assay, we used the hex , and therefore provides a direct determination of hex A activity. We noted that the MUGS assay was linear with respect to sample concentration, from 5 to 20 jig of sample protein, the range over which the percent hex A changed in the heat-inactivation assay, and that the specific activity of hex A in the sample was unaffected by the change in sample concentration (data not shown). We also determined whether the sample concentration could affect the rate of heat inactivation of hex A. Figure  3 shows the time course for the heat inactivation of hex A in one sample from a noncarrier, at four different sample concentrations, assayed with the MUGS substrate. At each sample concentration tested, the hex A rate of heat inactivation was the same. Similar results were obtained with a second noncarrier control (data not shown).
Discussion
This report describes an unusual and previously undocumented effect of sample concentration on the apparent activity of hex A when measured by the commonly used heat-inactivation assay. With increasing sample concentration, the percent of total hexosaminidase attributed to hex A decreased significantly when assayed in leukocytes from noncarriers of TSD and individuals heterozygous and homozygous for TSD. Our results indicate that hex B, but not hex A, is affected by the change in sample concentration.
Because the heat-inactivation assay indirectly measures hex A (total minus hex B), any effect on hex B would appear as an opposite effect on hex A. Three sets of data support this hypothesis.
First, when the effects of sample concentration in the heat-inactivation assay were studied in leukocytes from Sandhoff disease heterozygotes, the apparent decrease in the amount of hex A was much less than that seen in noncarriers and TSD carriers. Sandhoff disease carriers typically have a high percent of hex A and reduced total hexosaminidase activity because the mutation they carry is in the 13-subunit gene. The amount of hex B, which is made up of two /3 subunits, is greatly reduced in Sandhoff disease heterozygotes. Therefore, if the response to sample concentration is the result of an effect on hex B, one would expect to see less of a decrease in the amount of hex A in Sandhoff disease carriers, as was demonstrated in this study (Figure 2 ). Second, when hex A was assayed directly by using the hex A-specific substrate MUGS, we found no effect of sample concentration on hex A activity. The MUGS assay was linear with respect to sample concentration, and the same specific activity was observed at all sample concentrations tested. Also, when the rate of heat inactivation of hex A was examined, no differences were found when different sample concentrations were used. These data eliminate changes in hex A activity as the cause of the apparent decrease in the amount of hex A observed with the standard heat-inactivation assay. Finally, in a leukocyte sample from a TSD homozygote, in which little hex A exists, a similar concentration-dependent discrepancy in the apparent percentage of hex A was observed. Since hex B is nearly all of the hexosaminidase present in such a sample, this result is further evidence that the observations were due to effects on hex B and not hex A.
The apparent increase in hex A activity noted at low sample concentrations is the result of a decrease in hex B activity. This could be caused by a number of factors. At lower sample concentrations, hex B could be more heat-labile than at higher sample concentrations.
Since the heat-inactivation assay assumes that all activity lost during heat treatment is that of hex A, the inactivation of a portion of the hex B would appear as an increase in hex A. This effect would not be the result of a nonspecific stabilization by protein, because the inactivation assay is performed in the presence of a high concentration of BSA (4.8 g/L), so that the total protein concentration of the assay system is essentially the same for each concentration of sonicate. Another explanation is that hex B activity is protected or enhanced by a cellular component whose function as an effector is reduced at low sample concentrations and increased at high sample concentrations.
Such an effector could be a protein, a lipid, or other molecule. This explanation is also consistent with our data.
Variations in the percent of hex A pose a problem for the accurate diagnosis of TSD carrier status. The diagnosis of carrier or noncarrier status is determined by the percent of hex A in a patient's sample. In the case of persons who are truly noncarriers, a high sample concentration in the assay could yield an inconclusive or a false-positive result. Likewise, for persons who are truly TSD heterozygotes, a low sample concentration could yield an inconclusive or false-negative result. The former case can result in unnecessary anxiety in a person who is not really at risk to produce a child with TSD. In the latter case, the true risk is not known for that person and other family members. In addition, a very low concentration of leukocyte sample could cause a diseased patient to appear as a carrier.
The importance of the leukocyte (3-hexosaminidase assay in diagnosing carriers for a serious neurodegenerative disease and the marked effects of seemingly minor variations in sample concentration on the apparent concentration of the key analyte, hex A, underscore the need for stringent guidelines for the amount of sample used in the leukocyte TSD carrier test. Although there is no "right" amount of sample, we recommend using either a standard amount of sample protein (e.g., 10 jig per tube) or a range of 8 to 12 jig of sample protein per tube. Each testing laboratory should establish its own protocol and reference ranges to maximize test reliability.
Additionally, the use of DNA diagnostics for the molecular genetic analysis of common a subunit gene mutations may be a valuable adjunct in cases of patients whose test results are inconclusive after careful leukocyte hexosaminidase analysis (10-12).
